Biblio

Author Title [ Type

] Year

Filters: Author is Tessoulin, Benoit [Clear All Filters]

Journal Article

Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, et al. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. Am J Hematol. 2024.

Schroers-Martin JG, Alig S, Garofalo A, Tessoulin B, Sugio T, Alizadeh AA. Molecular Monitoring of Lymphomas. Annu Rev Pathol. 2022.

Sarkozy C, Thieblemont C, Obéric L, Moreau A, Bouabdallah K, Damaj G, Gastinne T, Tessoulin B, Ribrag V, Casasnovas O, et al. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. J Clin Oncol. 2023:JCO2301586.

Stathis A, Pirosa MCristina, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FGaia, Merli F, Guieze R, et al. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica. 2024.

Le Bourgeois A, Labopin M, Guillaume T, Delaunay J, Foucher Y, Tessoulin B, Malard F, Ayari S, Peterlin P, Derenne S, et al. HHV-6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. Exp Hematol. 2014.

Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert B-M, Daguindau E, Mahe B, Dubruille V, Blin N, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.

Jullien M, Le Bourgeois A, Coste-Burel M, Peterlin P, Garnier A, Rimbert M, Imbert B-M, Le Gouill S, Moreau P, Mahe B, et al. B-cell aplasia is the most powerful predictive marker for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccines in recipients of allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2022.

Laurent V, Fronteau C, Antier C, Dupuis P, Tessoulin B, Gastinne T, Mahe B, Blin N, Dubruille V, Lok A, et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2020.